Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Docetaxel].

Y Suzuki1, Y Tokuda

  • 1Department of Surgery, Tokai University School of Medicine, Boseidai, Isehara 259-1193, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
PubMed
Summary
This summary is machine-generated.

Docetaxel shows promise for advanced breast cancer, offering higher response rates than older treatments. Weekly administration may reduce severe side effects like neutropenia, improving treatment feasibility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Experimental study of indirect lymphography with iodinated starch].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

Participation of calpain I activation in the ATP release reaction of platelets stimulated with thrombin.

Biochimica et biophysica acta·1992
Same author

[Esophago-bronchial fistula caused by chemotherapy with bronchial artery infusion for pulmonary metastases from urinary tract cancer].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

[Antibacterial activity of rokitamycin against fresh clinical isolates].

The Japanese journal of antibiotics·1992
Same author

Radioactive cesium in dirt accumulations on the roof of buildings.

The Tokushima journal of experimental medicine·1992
Same author

Circadian variation in plasma homovanillic acid level during and after alcohol withdrawal in alcoholic patients.

Alcoholism, clinical and experimental research·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Anthracycline-based chemotherapy is standard for advanced or recurrent breast cancer.
  • Previous treatments like Mitomycin C and oral 5-FU show limited efficacy in refractory cases.

Purpose of the Study:

  • To evaluate docetaxel as a treatment option for advanced or recurrent breast cancer.
  • To assess the efficacy and safety of docetaxel, particularly in comparison to standard therapies.

Main Methods:

  • Review of phase II studies on docetaxel in metastatic breast cancer.
  • Analysis of response rates and toxicities, including myelosuppression and neutropenia.
  • Exploration of weekly docetaxel administration for managing side effects.

Main Results:

Related Experiment Videos

  • Docetaxel demonstrates high overall response rates (approx. 60% in untreated, 40% in anthracycline-refractory cases).
  • Common dose-limiting toxicity is myelosuppression, with high incidence of grade 3-4 neutropenia (90-95%) in standard 3-weekly regimens.
  • Weekly docetaxel administration shows potential for reducing myelosuppression severity.

    • Conclusions:

    • Docetaxel is a promising agent for advanced or recurrent breast cancer, offering improved response rates.
    • Myelosuppression is a significant toxicity, necessitating dose and schedule adjustments.
    • Weekly docetaxel administration is a feasible strategy to mitigate toxicity and enhance treatment tolerability.